Effects of ganglioside therapy on experimental CS2 neuropathy.
Both in animals and in man the inhalation of CS2 vapor induces a chronic polyneuropathy with primary lesions in the axons of peripheral nerves. Since it was reported in several studies that the administration of gangliosides improves nerve regeneration and the functional recovery of nerves damaged by section as well as cryodegeneration, a study was undertaken to evaluate the effects of bovine-brain gangliosides administration on the experimental CS2 neuropathy in the rat. One hundred and fifty male rats were intoxicated with CS2 by a discontinuous inhalation exposure to 700 ppm for 12 weeks until a clear neuropathy developed. Thereafter the animals were subdivided at random into five groups and treated in different ways: 10 mg/kg BW gangliosides, 0.5 mg/kg gangliosides, 0.5 mg/kg vitamin B1, and 1 mg/kg vitamin B6, physiological solution, and controls without any treatment. The recovery from neuropathy was controlled for 18 weeks of treatment and assessed periodically by means of clinical, electromyographic, and morphological examination. The results of morphological studies showed more pronounced regeneration activity in the rats treated with the high dose of gangliosides than in all others, while no differences among the groups could be observed as far as clinical and neurophysiological parameters are concerned. The mechanism supporting this ganglioside-induced effect has so far not been ascertained, and further studies on this subject are in progress.
D000818:Animals; D002246:Carbon Disulfide / Q000506:poisoning; D004359:Drug Therapy, Combination; D004576:Electromyography; D005732:Gangliosides / Q000627:therapeutic use*; D008297:Male; D009416:Nerve Regeneration / Q000187:drug effects*; D009431:Neural Conduction; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced / Q000188:drug therapy*; D010543:Peroneal Nerve / Q000648:ultrastructure; D011736:Pyridoxine / Q000627:therapeutic use; D051381:Rats; D011919:Rats, Inbred Strains; D013831:Thiamine / Q000627:therapeutic use
D005732:Gangliosides; D011736:Pyridoxine; D002246:Carbon Disulfide; D013831:Thiamine